CurrentMass General Brigham Health PlanPolicy N/A

Methadone oral solution prior authorization

Defines prior authorization, coverage criteria, and renewal requirements for methadone oral solution as an analgesic for severe/persistent pain under Mass General Brigham Health Plan pharmacy benefit.

Policy Summary

PayerMass General Brigham Health Plan

PolicyMethadone oral solution prior authorization

Policy CodePolicy N/A

Change TypeClarified trial requirementsremoved approval length for postoperative pain

Effective DateAug 1, 2025

Next Review DateJul 9, 2025

Key ActionObtain prior authorization and document diagnosis, prior medication trials (drug, dose, duration, dates), validated pain/function scores (e.g., Brief Pain Inventory), and substance use screening (e.g., DAST-10).

SourceLink

POLICY UPDATE CHANGES

For diagnosis of moderate to severe neuropathic pain or fibromyalgia, trial requirements with gabapentin and tricyclic antidepressants (TCAs) were clarified to require inadequate response.

Approval length for post-operative pain was removed.

6 moInitial approval length for non-cancer diagnoses

12 moApproval length for cancer/end-of-life

90 dNew-to-plan continuity window

DAST-10

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Medical Necessity Criteria

Initial authorization criteria

Covered when ONE of the following pathways is met

Continuity for new-to-plan: Member new to the plan within the past 90 days currently receiving the requested medication (excluding samples or manufacturer assistance programs).90 days

Continuity-of-care pathway

Cancer or end-of-life care: Diagnosis of cancer OR receiving opioids as part of end-of-life care.

If met, approval length is 12 months.

Non-cancer chronic pain (non-neuropathic): Member has moderate to severe chronic non-neuropathic pain AND inadequate response to 8 weeks of gabapentin titrated to therapeutic dose or contraindication to gabapentin (Document drug, dose, duration, and date of trial).gabapentin 8 weeks

Document drug(s), dose, duration, and date of trial.

Neuropathic pain or fibromyalgia: Member has moderate to severe neuropathic pain or fibromyalgia AND inadequate response to at least 6-8 weeks of a tricyclic antidepressant titrated to therapeutic dose or contraindication to a TCA (e.g., amitriptyline, nortriptyline, imipramine) (Document drug, dose, duration, and date of trial).TCA 6-8 weeks

Document drug(s), dose, duration, and date of trial.

Initial therapy additional requirements: For members filling the prescribed medication for the first time, an adequate (minimum 4 week) trial of a short-acting opioid must be documented unless member is established on the prescribed medication.short-acting opioid 4 weeks

Document drug(s), dose, duration, and date of trial.

Continuation therapy criteria

Reauthorization may be granted when ONE of the following is met

Cancer or end-of-life care continuation: Member is requesting medication for cancer or end-of-life care with treatment goals and estimated duration documented.

Reauthorization up to 12 months.

Other diagnoses continuation: Documentation addresses ALL: treatment plan includes nonopioid analgesic and/or nonpharmacologic intervention; meaningful improvement in pain and function using a validated instrument (e.g., Brief Pain Inventory); rationale for not tapering; substance use screening (e.g., DAST-10); screening for comorbid mental health conditions; prescriber assessment of respiratory depression risk when comorbidities or interacting drugs present; PDMP review showing no concurrent controlled substances if PDMP available; and total daily morphine milligram equivalent documented.

Reauthorization up to 6 months.

This policy excludes use of methadone oral solution as an as‑needed (PRN) analgesic, for pain that is mild or not expected to persist for an extended period of time, and for acute pain. Postoperative pain is also excluded except in two situations: the member was already receiving chronic opioid therapy prior to surgery, or the postoperative pain is expected to be moderate to severe and persist for an extended period of time. These exclusions reflect the intent that methadone oral solution is reserved for chronic, persistent pain requiring daily opioid therapy rather than short‑term or intermittent indications.

Use of methadone oral solution for mild pain, short‑duration pain, acute pain, or as an PRN (as‑needed) analgesic is explicitly stated as not medically necessary under this policy. The policy therefore will not approve methadone for indications that do not require extended daily opioid analgesia or for intermittent symptom control.

Pharmacy Identifiers and Trial Durations

Pharmacy/Program identifiers and benefitsmixed

No codes listed

Short-acting opioid trial — minimum 4 week trial

RequirementMembers filling the medication for the first time must have a documented adequate trial of a short-acting opioid for a minimum of 4 weeks (document drug, dose, duration, and date of trial)

ExceptionMembers already established on the prescribed medication are not required to have the short-acting opioid trial for continuation of therapy

PurposeDemonstrates prior adequate analgesic trial before initiating methadone oral solution

Gabapentin trial — 8 weeks titrated to therapeutic dose

RequirementFor non-neuropathic chronic pain, inadequate response to 8 weeks of gabapentin titrated to a therapeutic dose must be documented (include drug, dose, duration, and date of trial)

Alternative

Prior Authorization, Documentation, and Denial Conditions

Prior Authorization

Prior Authorization Required

Prior authorization is required. Continuity window: members new to the plan (within 90 days) who are currently receiving the requested medication may be authorized (excludes samples or manufacturer patient assistance program supply). Initial approvals: cancer/end-of-life — up to 12 months; all other diagnoses — up to 6 months. Reauthorizations: cancer/end-of-life — 12 months; all other diagnoses — 6 months.

Continuity window: 90 days for members new to plan receiving therapy
Initial approval durations: cancer/end-of-life = 12 months; other = 6 months
Reauthorization durations: cancer/end-of-life = 12 months; other = 6 months

Step Therapy

Step Therapy / Trial Requirements

Step therapy requires documented trials of specified alternatives (drug name, dose, duration, and dates). For non-cancer diagnoses the member must meet one of the following: 1) Moderate to severe chronic non‑neuropathic pain with inadequate response to an 8‑week trial of gabapentin titrated to therapeutic dose or documented contraindication; OR 2) Moderate to severe neuropathic pain or fibromyalgia with inadequate response to a 6–8 week trial of a tricyclic antidepressant (eg, amitriptyline, nortriptyline, imipramine) titrated to therapeutic dose or documented contraindication. For members filling the prescribed medication for the first time prior to start of therapy, an adequate minimum 4‑week trial of a short‑acting opioid must be documented where applicable.

Required Trials and Nonpharmacologic Inclusion for Reauthorization

Document inadequate response or contraindication to specified alternatives and include nonopioid/nonpharmacologic therapies in treatment plan for reauthorization

Document inadequate response or contraindication to specified alternatives and include nonopioid/nonpharmacologic therapies in treatment plan for reauthorization.

Gabapentin trial: Document inadequate response to or contraindication to gabapentin titrated to a therapeutic dose for 8 weeks for moderate to severe non-neuropathic chronic pain.gabapentin 8 weeks

Document drug(s), dose, duration, and date of trial.

Tricyclic antidepressant (TCA) trial: Document inadequate response to or contraindication to a tricyclic antidepressant (e.g., amitriptyline, nortriptyline, imipramine) titrated to a therapeutic dose for at least 6-8 weeks for neuropathic pain or fibromyalgia.TCA 6-8 weeks

Document drug(s), dose, duration, and date of trial.

Approval Duration and Reauthorization Intervals

Medication approval duration — initial and reauthorization intervals defined (6 or 12 months)

Initial approval durations12 months for cancer or end-of-life care; 6 months for all other diagnoses

Reauthorization intervalsReauthorizations: 12 months for cancer/end-of-life care; 6 months for all other diagnoses

ApproachApproval durations are defined as fixed intervals (6 or 12 months) rather than per‑procedure frequency limits

Imaging and Diagnostics

Note

Imaging requirements

No imaging requirements specified in the policy.

Clinical Background and Indications

Methadone oral solution is indicated for the management of severe, persistent pain that requires an extended period of daily opioid analgesia when alternative treatments are inadequate. The policy distinguishes cancer/end‑of‑life care from other chronic pain diagnoses, and requires documentation of prior trials or continuity of care before authorization is granted.

Key Definitions and Indications

Indication — management of severe and persistent pain requiring extended daily opioid analgesia

IndicationManagement of severe and persistent pain requiring extended daily opioid analgesia when alternative treatments are inadequate

ScopeUsed for patients who require an extended treatment period with a daily opioid analgesic

DistinctionPolicy distinguishes cancer/end-of-life care from other chronic pain diagnoses for approval length and criteria

Services and Uses Not Covered

NOT COVERED: Methadone oral solution will not be approved for use as an as‑needed (PRN) analgesic, for mild or short‑duration pain, or for acute pain. Postoperative pain is not covered except when the member was already receiving chronic opioid therapy prior to surgery or when postoperative pain is expected to be moderate to severe and persist for an extended period of time. These limitations align with the policy requirement that methadone be reserved for patients requiring ongoing daily opioid treatment rather than transient or intermittent indications.